Has Renu Lamba, MD received payments from drug or device companies?

Yes. Drug and device makers reported $94 in general payments to Renu Lamba, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Renu Lamba, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Renu Lamba, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Renu Lamba, MD

Medical Oncology · Bayonne, NJNPI 1801828330

Payments from drug & device makers

$94in general payments, 2019–2025

Across 6 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$69
Octapharma USA, Inc.$13
Heron Therapeutics, Inc.$12

What the payments were for

Food & beverage$94100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	4	$69
Octapharma USA, Inc.	1	$13
Heron Therapeutics, Inc.	1	$12

How this compares

$94 in reported general payments places this provider in the 10th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$551,287

Medicare patients

Services billed

63,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	20	$154,580
ProcritEpoetin Alfa	23	$96,929
Abiraterone Acetate	12	$72,720
Imatinib Mesylate	12	$62,325
ZirabevBevacizumab-Bvzr	12	$40,696
EliquisApixaban	15	$9,702
Fosaprepitant Dimeglumine	19	$2,556
Ropinirole Hcl	39	$546
ValacyclovirValacyclovir Hcl	16	$485
Famotidine	63	$348
Losartan Potassium	39	$343
Atorvastatin Calcium	23	$323
Oxycodone Hcl	13	$265
Levothyroxine Sodium	39	$263
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide	18	$237

Paid to pharmacies, not to this prescriber.

Other medical oncology in Bayonne

Martin GutierrezHackensack$41.8M
James McCloskeyHackensack$17.1M
Lori LeslieHackensack$11.9M
Tatyana FeldmanHackensack$8.4M
Benjamin FreemanMorristown$7.5M
Kristen SpencerNew Brunswick$7.2M
David SiegelHackensack$6.9M
Biren SaraiyaNew Brunswick$6.2M
Noa BiranHackensack$5.8M
Sanjay GoelNew Brunswick$5.1M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →